

# A descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

<b>Submission date</b> 24/04/2012	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 26/07/2012	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 29/03/2018	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This is a research study being carried out at six hospitals in the UK. It will look back over 3 years at how well patients with multiple sclerosis (MS) respond to medicines known as disease modifying therapies (DMTs), which are used to treat MS. We are also looking at the effect a relapse has on the everyday life of a person with MS. DMTs have all been tested in clinical trials and approved for treating patients, but in this study we want to get more information about the experience of patients using them. This study is designed to increase understanding of how well DMTs work as initial treatments for Relapsing Remitting MS (RRMS), in patients real-world setting rather than in formal clinical trials.

We understand the progression and accumulation of disability in the later stages of MS quite well, but the physical, psychological and financial impact of relapses in early disease is less clear and potentially underestimated. Differing perceptions between physicians and patients on the nature and severity of a relapse may contribute to this.

### Who can participate?

Patients with a diagnosis of RRMS, and who started a DMT for the first time in 2008, will be eligible to participate.

### What does the study involve?

Patients will be identified at 6 UK centres and will be invited to participate by post. They will be sent an information sheet, and details of a person to contact if they require further information. Once the consent has been returned (by post), the participant will be enrolled in the study and will receive another package by post. Included in this pack are a retrospective questionnaire to provide information on the participants experience of their last relapse, and three short questionnaires to inform us of their current health status. Once this is returned, the participant will have completed their role in study.

We will also look at the medical records of those who allow us to do so. We will look at the number of relapses that occur in the 3 years after the first prescription of DMTs, any changes in medication, and the number of clinic visits needed during this time.

What are the possible benefits and risks of participating?

There are no direct risks or benefits to the participant in this study as there will be no change in patient care. The benefit is adding to the literature in this area to inform clinical and policy decisions about patient care.

Where is the study run from?

This study is coordinated independently by pH Associates. The six centres taking part will be: The Royal Victoria Infirmary - Newcastle, Queens Hospital - Romford, Charing Cross Hospital - London, Leicester General Infirmary - Leicester, Norfolk and Norwich University Hospital Norwich, and Morrysten Hospital - Swansea.

When is study starting and how long is it expected to run for?

May 2012 to December 2012.

Who is funding the study?

Novartis Pharmaceuticals UK Ltd (UK)

Who is the main contact?

Heather Davies

heather.davies@novartis.com

Lucinda Davies (pH Associates)

lucinda@phassociates.com

## Contact information

### Type(s)

Scientific

### Contact name

Dr Heather Davies

### Contact details

Novartis Pharmaceuticals UK Ltd

200 Frimley Business Park

Frimley

United Kingdom

GU16 7SR

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

CFTY720DGB02

# Study information

## Scientific Title

A multi-centre observational study of relapsing-remitting multiple sclerosis (RRMS) treated with first disease modifying therapies (DMTs) in current UK clinical practice: patterns of clinical decision making and the patient experience of relapse

## Study objectives

To describe the number of documented relapses experienced by people with MS (PwMS) in the first 3 years following DMT initiation

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Yes - London-Bromley, approved 4th April 2012, ref: 12 LO 0248

## Study design

Multi-centre observational study

## Primary study design

Observational

## Secondary study design

Other

## Study setting(s)

GP practice

## Study type(s)

Screening

## Participant information sheet

## Health condition(s) or problem(s) studied

Multiple Sclerosis

## Interventions

1. Retrospective questionnaire on the patients experience of the last relapse
2. Three short health questionnaires
3. Review of medical records over 3 years from the first prescription of a disease-modifying treatment for relapsing-remitting multiple sclerosis

## Intervention Type

Other

## Phase

Not Applicable

### **Primary outcome measure**

To describe the number of documented relapses experienced by patients with MS in the first 3 years following DMT initiation

### **Secondary outcome measures**

1. To describe the number of documented relapses experienced by patients with MS in the 3 years following DMT initiation by severity
2. To describe the DMT prescribing patterns in the first three years following DMT initiation
3. To compare clinician-documented and patient-reported relapse symptoms
4. To describe the change in patient contact with health care professionals resulting from relapse
5. To describe the financial impact of a relapse on patients with MS
6. To describe the impact of a relapse on patients attitudes to DMT

### **Overall study start date**

01/06/2012

### **Completion date**

01/12/2012

## **Eligibility**

### **Key inclusion criteria**

1. Patients with RRMS by 2005 MacDonald criteria
2. Patients initiated on DMT for the first time after 1 January 2008 and at least 36 months before date of screening for inclusion
3. Patients who consent to complete the questionnaire and for their medical records to be reviewed for the purposes of healthcare research
4. Patients who are able to complete the study questionnaires or have a carer who is able and willing to record the patients responses to the study questionnaires

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Both

### **Target number of participants**

150

### **Key exclusion criteria**

1. Patients who are unwilling or unable to provide patient consent
2. Patients who are unable to complete the study questionnaires themselves and have no appropriate carer able and willing to assist them

### **Date of first enrolment**

01/06/2012

**Date of final enrolment**

01/12/2012

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Novartis Pharmaceuticals UK Ltd

Frimley

United Kingdom

GU16 7SR

## Sponsor information

**Organisation**

Novartis Pharmaceuticals Ltd (UK)

**Sponsor details**

c/o Dr Heather Davies

200 Frimley Business Park

Frimley

United Kingdom

GU16 7SR

+44 1276 694402

heather.davies@novartis.com

**Sponsor type**

Industry

**ROR**

<https://ror.org/039s6n838>

## Funder(s)

**Funder type**

Industry

**Funder Name**

Novartis Pharmaceuticals UK Ltd (UK)

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration